Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 46.50
Change Today +1.90 / 4.26%
Volume 1.9M
As of 10:24 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

medigus ltd (MDGS) Snapshot

Open
$44.90
Previous Close
$44.60
Day High
$47.40
Day Low
$44.00
52 Week High
04/14/15 - $58.90
52 Week Low
12/30/14 - $25.00
Market Cap
116.2M
Average Volume 10 Days
500.0K
EPS TTM
$-0.11
Shares Outstanding
249.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIGUS LTD (MDGS)

Related News

No related news articles were found.

medigus ltd (MDGS) Related Businessweek News

No Related Businessweek News Found

medigus ltd (MDGS) Details

Medigus Ltd., a medical device company, designs, develops, and sells endoscopic procedures and devices. The company offers Medigus Ultrasonic Surgical Endostapler system, an endoscope device comprising a surgical stapler, miniature camera, and an ultrasound sensor for incisionless treatment of gastroesophageal reflux disease. Medigus Ltd. was founded in 2000 and is headquartered in Omer, Israel.

Founded in 2000

medigus ltd (MDGS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 1.9M
Founder and Global Chief Operating Officer
Total Annual Compensation: 1.1M
Chief Financial Officer
Total Annual Compensation: 630.0K
Executive Vice President
Total Annual Compensation: 523.0K
Chief Technology Officer
Total Annual Compensation: 635.0K
Compensation as of Fiscal Year 2014.

medigus ltd (MDGS) Key Developments

MediGus Ltd. Announces Executive Changes

On June 1, 2015, MediGus Ltd. announced that Mr. Thomas A. Dempsey was terminated from his position and ceased serving as VP U.S. effective June 1, 2015. Mr. Jeremy S. Starkweather was appointed VP of US Sales & Marketing effective as of June 1, 2015. Mr. Starkweather has more than 15 years of medical device sales & marketing experience. Prior to joining Medigus, Jeremy was the Vice-President of Sales & Business Development at Xlumena. He led the US launch and commercialization efforts for the AXIOS Stent. He held multiple positions in sales, marketing, & market development.

MediGus Ltd. Announces Executive Changes

Upon the completion of Gabby Sarusi's third three-year term as external director (which is the maximum permissible tenure under the Israeli Companies Law), the board of directors of MediGus Ltd. decided to fill the vacancy on the board via appointment by the board of directors in accordance with Section 93 of the company's articles of association, and to appoint Mr. Doron Birger as a regular director at the company, as of May 17, 2015 until the company's next annual general meeting of the shareholders. Mr. Birger currently serves as a director of Hadasit Bio-Holdings Ltd. and Icecure Medical Ltd. and as chairman and director of several private companies in Israel in the high-technology sector mainly in the medical device field. The board of directors of the company appointed Mr. Birger to each of the Audit Committee, the Compensation Committee and the Financial Statements Examination Committee of the company.

Medigus Ltd. Announces Availability of MUSE(TM) Procedure for the Treatment of GERD in Germany

Medigus Ltd. announced the third MUSE - procedure in a three-month period was completed in Germany. Renowned gastroenterologist, Professor Doctor Karel Caca at the Clinic for Internal Medicine, Gastroenterology, Haemato-Oncology, Diabetes and Infectious Disease, recently adopted this new technology to offer his patients the most innovative care. The Medigus Ultrasonic Surgical Endostapler, or MUSE, is an incisionless procedure for the treatment of gastroesophageal reflux disease (GERD). Medigus has merged recent technological breakthroughs into a single platform with MUSE. The device is fully integrated with leading microvisual, ultrasonic and stapling technology, and therefore allows a single physician or surgeon to perform fundoplication (stapling of the upper part of the stomach, or fundus, to the lower esophageal sphincter), thereby offering a long-term, potentially permanent solution for GERD.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGS:IT 46.50 +1.90

MDGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGS.
View Industry Companies
 

Industry Analysis

MDGS

Industry Average

Valuation MDGS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIGUS LTD, please visit www.medigus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.